Edges in Network
| Network | GSE16446_egf1520 - GSE16446 - SiGN-BN HC+Bootstrap |
| Network Description | Predicting the efficacy of anthracyclines in breast cancer (BC) patients: The results of the TOP trial |
| Node | ARSJ |
| Upstream (Parents) |
|---|
| (<<) ABLIM1 → ARSJ |
| (<<) APC2 → ARSJ |
| (<<) BCAR3 → ARSJ |
| (<<) BPGM → ARSJ |
| (<<) CDR2 → ARSJ |
| (<<) CEND1 → ARSJ |
| (<<) DEPDC7 → ARSJ |
| (<<) DUSP6 → ARSJ |
| (<<) EREG → ARSJ |
| (<<) FGF1 → ARSJ |
| (<<) HEY1 → ARSJ |
| (<<) HLA-G → ARSJ |
| (<<) JAG1 → ARSJ |
| (<<) MAFF → ARSJ |
| (<<) MGC45922 → ARSJ |
| (<<) MTMR6 → ARSJ |
| (<<) MTSS1 → ARSJ |
| (<<) MYO1E → ARSJ |
| (<<) NFATC4 → ARSJ |
| (<<) NFKB2 → ARSJ |
| (<<) PARD6G → ARSJ |
| (<<) PARP10 → ARSJ |
| (<<) PCDH7 → ARSJ |
| (<<) PLA2G12A → ARSJ |
| (<<) PPP3CA → ARSJ |
| (<<) RPIA → ARSJ |
| (<<) RPS6KA4 → ARSJ |
| (<<) SGMS2 → ARSJ |
| (<<) SLC5A1 → ARSJ |
| (<<) SOCS5 → ARSJ |
| (<<) SOCS6 → ARSJ |
| (<<) TGFB2 → ARSJ |
| (<<) TPM2 → ARSJ |
| (<<) UBE2L6 → ARSJ |
| (<<) VIM → ARSJ |
| Downstream (Children) |
|---|
| ARSJ → ERRFI1 (>>) |
| ARSJ → FGF3 (>>) |
| ARSJ → HAS3 (>>) |
| ARSJ → PLD1 (>>) |
| ARSJ → THRB (>>) |
